<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04574492</url>
  </required_header>
  <id_info>
    <org_study_id>P20-096</org_study_id>
    <nct_id>NCT04574492</nct_id>
  </id_info>
  <brief_title>A Study of Oral Upadacitinib Tablets to Assess the Change in Disease Symptoms in Adult Canadian Participants With Moderate to Severe Rheumatoid Arthritis</brief_title>
  <acronym>CLOSEUP</acronym>
  <official_title>Canadian Real-life Post-marketing Observational Study Assessing the Effectiveness of Upadacitinib for Treating Rheumatoid Arthritis (CLOSEUP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rheumatoid Arthritis (RA) is an inflammatory disease of the joints causing pain, stiffness,&#xD;
      swelling and loss of joint function. This study will assess how effective Upadacitinib is in&#xD;
      changing the disease symptoms in Canadian participants with RA.&#xD;
&#xD;
      Upadacitinib is a drug approved for the treatment of moderately to severely active rheumatoid&#xD;
      arthritis. Adult Canadian participants with moderate to severe RA who have been prescribed&#xD;
      upadacitinib by their physicians will be enrolled. Approximately, 390 participants will be&#xD;
      enrolled this study, in multiple sites within Canada.&#xD;
&#xD;
      Participants will receive Upadacitinib as prescribed by the physician and will be followed&#xD;
      for approximately 24 months.&#xD;
&#xD;
      There will be no additional burden for participants in this trial compared to their standard&#xD;
      of care. Participants will attend regular visits during the course of the study at a hospital&#xD;
      or clinic and will be asked to provide additional information by questionnaire at each visit.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 7, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Achieve Clinical Remission</measure>
    <time_frame>At Month 6</time_frame>
    <description>Clinical remission is defined as Disease Activity Score at 28 joints (DAS28) C-reactive Protein (CRP)&lt;2.6.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Pain Using Visual Analogue Scale (VAS)</measure>
    <time_frame>Baseline (Month 0) Through Month 24</time_frame>
    <description>Pain is defined using VAS, where a higher score indicates worse pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Morning Stiffness</measure>
    <time_frame>Baseline (Month 0) Through Month 24</time_frame>
    <description>Duration of morning joint stiffness is defined using VAS, where a higher score indicates worse joint stiffness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Morning Stiffness</measure>
    <time_frame>Baseline (Month 0) Through Month 24</time_frame>
    <description>Severity of morning joint stiffness is defined using VAS, where a higher score indicates worse joint stiffness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F)</measure>
    <time_frame>Baseline (Month 0) Through Month 24</time_frame>
    <description>The FACIT Fatigue Scale is a short, 13-item, easy to administer tool that measures an individual's level of fatigue during their usual daily activities over the past week. The level of fatigue is measured on a four-point Likert scale (0 = not at all fatigued to 4 = very much fatigued).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Clinical Remission</measure>
    <time_frame>Baseline (Month 0) Through Month 24</time_frame>
    <description>Clinical Remission is defined as DAS28-CRP&lt;2.6, Simplified Disease Activity Index (SDAI) ≤3.3, Clinical Disease Activity Index (CDAI) ≤2.8, American College of Rheumatology (ACR)-European League Against Rheumatism (EULAR) Boolean remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Low Disease Activity (LDA)</measure>
    <time_frame>Baseline (Month 0) Through Month 24</time_frame>
    <description>LDA is defined as DAS28-CRP&lt;3.2, SDAI ≤11, CDAI ≤10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Earliest Date When a Response to Treatment is Known to Have Occurred</measure>
    <time_frame>Baseline (Month 0) Through Month 24</time_frame>
    <description>Earliest date when a response to treatment is known to have occurred.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Earliest Date When Their RA is Known to have Returned (In those Participants who Achieve a Response to Treatment)</measure>
    <time_frame>Through Month 24</time_frame>
    <description>Earliest date when their RA is known to have returned (In those participants who achieve a response to treatment).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in DAS28-CRP Score</measure>
    <time_frame>Baseline (Month 0) Through Month 24</time_frame>
    <description>The DAS28-CRP used to evaluate disease activity in participants with RA, where worsening RA activity is defined by a higher score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CDAI Score</measure>
    <time_frame>Baseline (Month 0) Through Month 24</time_frame>
    <description>The CDAI is used to evaluate disease activity in participants with RA , where worsening RA activity is defined by a higher score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Tender Joint Count</measure>
    <time_frame>Baseline (Month 0) Through Month 24</time_frame>
    <description>Change in Tender Joint Count.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Swollen Joint Count</measure>
    <time_frame>Baseline (Month 0) Through Month 24</time_frame>
    <description>Change in Swollen Joint Count.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Physical Function (HAQ-DI) Score</measure>
    <time_frame>Baseline (Month 0) Through Month 24</time_frame>
    <description>The HAQ DI is a questionnaire that determines physical function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient Assessment of Global Disease Activity (PtGA)</measure>
    <time_frame>Baseline (Month 0) Through Month 24</time_frame>
    <description>The PtGA is a outcome instrument to assess the participant's assessment of disease severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Physician Assessment of Global Disease Activity (PGA)</measure>
    <time_frame>Baseline (Month 0) Through Month 24</time_frame>
    <description>The PGA is a outcome instrument to assess the participant's assessment of disease severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Discontinue Upadacitinib</measure>
    <time_frame>Through Month 24</time_frame>
    <description>Percentage of participants who discontinue Upadacitinib.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Discontinuation from Upadacitinib Initiation Date</measure>
    <time_frame>Through Month 24</time_frame>
    <description>Time of discontinuation from Upadacitinib initiation date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reasons for Upadacitinib Treatment Discontinuation</measure>
    <time_frame>Through Month 24</time_frame>
    <description>Reasons for Upadacitinib treatment discontinuation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immediate Change in RA Medications Following Discontinuation of Upadacitinib</measure>
    <time_frame>Through Month 24</time_frame>
    <description>Immediate change in RA medications following discontinuation of Upadacitinib.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieve Sustained Remission Following Discontinuation of Upadacitinib</measure>
    <time_frame>Through Month 24</time_frame>
    <description>Clinical remission is defined as DAS28 and CRP&lt;2.6.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">390</enrollment>
  <condition>Rheumatoid Arthritis (RA)</condition>
  <arm_group>
    <arm_group_label>Participants receiving Upadacitinib</arm_group_label>
    <description>Participants receiving Upadacitinib for moderate to severe rheumatoid arthritis (RA).</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Participants receiving Upadacitinib according to the product prescribing information, for&#xD;
        moderate to severe active Rheumatoid Arthritis (RA).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of moderate to severe Rheumatoid Arthritis (RA) according to the&#xD;
             investigator.&#xD;
&#xD;
          -  Decision to initiate UPA treatment by investigator according to the local product&#xD;
             label independent of the participant's participation in the study.&#xD;
&#xD;
          -  Has been previously treated with Conventional Synthetic Disease-Modifying&#xD;
             Antirheumatic Drugs (csDMARDs) and corresponds to one of the following subgroups:&#xD;
&#xD;
               -  Has not been previously exposed to any Biologic Disease-Modifying Antirheumatic&#xD;
                  Drugs (bDMARD) or Targeted Synthetic Disease-Modifying Antirheumatic Drugs&#xD;
                  (tsDMARD).&#xD;
&#xD;
               -  Has not been previously exposed to tsDMARD and has been previously exposed to &lt;=&#xD;
                  2 bDMARDs.&#xD;
&#xD;
               -  Has been previously treated with one tsDMARD and &lt;=1 bDMARD prior to treatment&#xD;
                  with that tsDMARD.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of any condition that, in the opinion of the treating physician, prohibits&#xD;
             the participant from participating in the study or obscures the assessment of the&#xD;
             treatment of RA.&#xD;
&#xD;
          -  Diagnosis of rheumatic disease other than RA.&#xD;
&#xD;
          -  Diagnosis of juvenile RA.&#xD;
&#xD;
          -  Currently participating in an investigational clinical trial.&#xD;
&#xD;
          -  Has prior exposure to a bDMARD after exposure to a tsDMARD.&#xD;
&#xD;
          -  Has prior exposure to tsDMARD in an investigational clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ABBVIE INC.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>844-663-3742</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rheumatology Research Associates /ID# 224534</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5M 0H4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saurash Reddy Professional Corporation /ID# 225288</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 0T2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fraser Clinical Trials Inc /ID# 225200</name>
      <address>
        <city>New Westminster</city>
        <state>British Columbia</state>
        <zip>V3L 3W4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. Jonathan D. Chan Inc. /ID# 222976</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1J9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. Milton F. Baker Inc. /ID# 224555</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8P 5P6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Manitoba Clinic /ID# 223288</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1M3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eastern Regional Health Authority /ID# 223911</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nexus Clinical Research /ID# 225896</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 5E8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. Juris Lazovskis Inc. /ID# 224817</name>
      <address>
        <city>Sydney</city>
        <state>Nova Scotia</state>
        <zip>B1S 3N1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. Viktoria Pavlova Medicine Professional Corporation /ID# 224536</name>
      <address>
        <city>Ancaster</city>
        <state>Ontario</state>
        <zip>L9G 3K9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Waterside Clinic /ID# 224205</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 6L2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Drs. Rai &amp; Sekhon Medicine Professional Corporation /ID# 224366</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6R 0W3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. Sankalp V. Bhavsar Medicine Professional Corporation /ID# 223952</name>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <zip>L7R 2H3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Paolo Pace Medicine Professional Corporation /ID# 234057</name>
      <address>
        <city>Cambridge</city>
        <state>Ontario</state>
        <zip>N1R 4S1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. Chrisostomos Kouroukis &amp; Dr. Pauline Boulos MPC /ID# 223814</name>
      <address>
        <city>Dundas</city>
        <state>Ontario</state>
        <zip>L9H 1B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arthur Karasik Medicine Professional Corporation /ID# 225276</name>
      <address>
        <city>Etobicoke</city>
        <state>Ontario</state>
        <zip>M9C 5N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Adachi Medicine Prof. Corp /ID# 223872</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Healthcare /ID# 224042</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>West Mountain Medical Center /ID# 222975</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L9C 5N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Brandusa Florica Medicine Professional Corporation /ID# 222173</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5A 3V8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Credit Valley Rheumatology /ID# 219226</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5M 2V8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Imtiaz MS Khan Medicine Prof /ID# 225275</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5M 4N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rajwinder S. Dhillon Medicine /ID# 224365</name>
      <address>
        <city>Niagara Falls</city>
        <state>Ontario</state>
        <zip>L2E 6A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Makhzoum Medicine Professional Corporation /Id# 229629</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6H 3P1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. S. Gill Medicine Professional Corporation /ID# 225238</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6M 1M1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Dr. L. Lisnevskaia Medicine Professional Corporation /ID# 225645</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1H 1B9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Angela Montgomery Medicine Professional Corporation /ID# 231142</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 7X3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Niagara Peninsula Arthritis Ct /ID# 221472</name>
      <address>
        <city>St. Catharines</city>
        <state>Ontario</state>
        <zip>L2N 7E4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. Sabeen Anwar Medicine Professional Corporation /ID# 224797</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8X 1T3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CIUSSS de l'est de l'Ile-de-Montreal - Hopital Maisonneuve-Rosemont /ID# 225021</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rheumatology Institute of Montreal /ID# 224045</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Clinique de Rhumatologie de Montreal /ID# 221266</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4N 1C6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Applied Medical Informatics Research Inc. (AMIR) /ID# 224321</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4A 3T2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Rhumatologie de l'Est /ID# 224681</name>
      <address>
        <city>Rimouski</city>
        <state>Quebec</state>
        <zip>G5L 8W1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Groupe de Recherche en Maladies Osseuses Inc /ID# 222977</name>
      <address>
        <city>Sainte-foy</city>
        <state>Quebec</state>
        <zip>G1V 3M7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CIUSSS de l'Estrie - CHUS /ID# 225404</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1G 2E8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre de Recherche Musculo-Squelettique /ID# 224513</name>
      <address>
        <city>Trois-rivières</city>
        <state>Quebec</state>
        <zip>G8Z 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rheumatology Associates /ID# 228584</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7K 0H6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. Latha Naik /ID# 221195</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7K 3H3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>https://www.rxabbvie.com/</url>
    <description>Related Info.</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 29, 2020</study_first_submitted>
  <study_first_submitted_qc>September 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Upadacitinib</keyword>
  <keyword>RINVOQ</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

